Početna › Meduloblastom
Kliničke studije za Meduloblastom koje traže sudionike u SAD-u
24 studija za Meduloblastom traži sudionike na lokacijama širom Sjedinjenih Američkih Država.
Gradovi s najviše studija
- Washington, DC9 studija
- St. Louis, MO6 studija
- Houston, TX4 studija
- New York City, NY4 studija
- Seattle, WA4 studija
- Philadelphia, PA4 studija
- Durham, NC4 studija
- Miami, FL4 studija
- Tampa, FL4 studija
- Memphis, TN3 studija
- Boston, MA3 studija
- Chicago, IL3 studija
- Columbus, OH3 studija
- Cincinnati, OH3 studija
- Ann Arbor, MI3 studija
- Austin, TX3 studija
- Minneapolis, MN3 studija
- Hartford, CT3 studija
- Charlotte, NC3 studija
- Little Rock, AR3 studija
- Dallas, TX3 studija
- Orlando, FL3 studija
- St. Petersburg, FL3 studija
- San Diego, CA3 studija
- San Francisco, CA3 studija
- Mountain View, CA3 studija
Po državama
- Alabama3 studija
- Arkansas3 studija
- Connecticut3 studija
- Distrikt Columbia7 studija
- Florida6 studija
- Georgia3 studija
- Illinois3 studija
- Kalifornija6 studija
- Kentucky3 studija
- Maryland4 studija
- Massachusetts3 studija
- Michigan4 studija
- Minnesota3 studija
- Missouri6 studija
- New Jersey3 studija
- New York5 studija
- North Carolina4 studija
- Ohio3 studija
- Pennsylvania5 studija
- Tennessee5 studija
- Texas8 studija
- Washington4 studija
Nedavno ažurirane studije
Službeni tekst studije (engleski)
Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
U tijeku regrutacijaFaza 1/2
Od 1 do 25 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT07346157Cognitive Rehabilitation for Survivors of Childhood Medulloblastoma Using Real Time Hemodynamic Neurofeedback
U tijeku regrutacija
Od 10 do 25 godina · Oba spola · Ažurirano 23. ruj 2026. · NCT07830134Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
U tijeku regrutacijaFaza 2
59 Months · Oba spola · Ažurirano 15. ruj 2026. · NCT05535166GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
U tijeku regrutacijaFaza 1
Od 1 do 30 godina · Oba spola · Ažurirano 11. ruj 2026. · NCT07087002Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
U tijeku regrutacijaFaza 2
Do 19 godina · Oba spola · Ažurirano 10. ruj 2026. · NCT01356290HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
U tijeku regrutacijaFaza 1
36 Months – 22 Years · Oba spola · Ažurirano 4. ruj 2026. · NCT03911388B7-H3.CD28Z.CART in CNS Neoplasms
U tijeku regrutacijaFaza 1
Od 2 do 21 godina · Oba spola · Ažurirano 3. ruj 2026. · NCT07390539Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study
U tijeku regrutacijaOpažajna studija
Od 3 do 50 godina · Oba spola · Ažurirano 1. ruj 2026. · NCT07242963Digoxin Medulloblastoma Study
U tijeku regrutacijaFaza 2
12 Months – 30 Years · Oba spola · Ažurirano 26. kol 2026. · NCT06701812A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
U tijeku regrutacijaFaza 3
Od 4 do 21 godina · Oba spola · Ažurirano 25. kol 2026. · NCT05382338PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
U tijeku regrutacijaFaza 2
Od 3 do 39 godina · Oba spola · Ažurirano 24. kol 2026. · NCT05096481PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
U tijeku regrutacijaFaza 1/2
Od 18 do 120 godina · Oba spola · Ažurirano 12. kol 2026. · NCT06161519DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
U tijeku regrutacijaFaza 2
Do 21 godina · Oba spola · Ažurirano 12. kol 2026. · NCT04696029Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
U tijeku regrutacija
12 Months – 39 Years · Oba spola · Ažurirano 11. kol 2026. · NCT05057702Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma
U tijeku regrutacijaFaza 1
Od 4 do 30 godina · Oba spola · Ažurirano 7. kol 2026. · NCT06514898Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
U tijeku regrutacijaFaza 1
Od 2 do 25 godina · Oba spola · Ažurirano 3. kol 2026. · NCT06624371Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
U tijeku regrutacijaFaza 1/2
Od 4 do 39 godina · Oba spola · Ažurirano 20. srp 2026. · NCT05278208A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
U tijeku regrutacijaFaza 1
Od 3 do 22 godina · Oba spola · Ažurirano 13. srp 2026. · NCT07698899CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 6. srp 2026. · NCT07085325Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
U tijeku regrutacijaFaza 1
Od 1 do 30 godina · Oba spola · Ažurirano 17. lip 2026. · NCT06193759Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
U tijeku regrutacijaFaza 1
Od 1 do 26 godina · Oba spola · Ažurirano 13. tra 2026. · NCT04185038Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
U tijeku regrutacijaFaza 1
Od 3 do 25 godina · Oba spola · Ažurirano 9. sij 2026. · NCT05106296Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 18. pro 2025. · NCT0454108268-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
U tijeku regrutacijaFaza 4
Od 18 do 100 godina · Oba spola · Ažurirano 21. stu 2025. · NCT04081701Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.